AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1303534 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 29
Study 4058985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 4.0 mg/d
Number of subjects: 20
Study 4058985 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 0.5 mg/d
Number of subjects: 20
Study 4058985 — intervention group
Group type: EXPERIMENTAL
Intervention: All women (regardless of treatment)
Number of subjects: 20
Study 4058985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally relevant doses of vitamin B6
Number of subjects: 20
Study 30272844 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate solution (10% glucose water; 5, 10, and 15 mL/kg) administered 2 hours before anesthesia
Number of subjects: 1200
Study 30272844 — intervention group
Group type: COMPARATOR
Intervention: Control group (strictly restricted to 6-h preoperative fasting)
Number of subjects: 1200
Study 30272844 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 1200
Study 27230269 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Nutrition Facts Labels (NFLs)
Number of subjects: 155
Study 27230269 — intervention group
Group type: COMPARATOR
Intervention: Existing Nutrition Facts Labels (NFLs)
Number of subjects: 155
Study 27230269 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified NFLs (specifically relocating the percent daily value component)
Number of subjects: 155
Study 27230269 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed 'added sugars' component
Number of subjects: 155
Study 25480344 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin 8,000 IU aXa per day
Number of subjects: 117
Study 25480344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 22869285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (comprehensive dietary modification aimed at lowering insulin levels, including cooking classes and meals at the study center at least twice per week)
Number of subjects: 96
Study 22869285 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet without intervention)
Number of subjects: 96
Study 19926964 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278 25 mg once daily
Number of subjects: 368
Study 19926964 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278 75 mg once daily
Number of subjects: 368
Study 19926964 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278 150 mg once daily
Number of subjects: 368
Study 19926964 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily (control)
Number of subjects: 368
Study 19926964 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278 (all doses)
Number of subjects: 368
Study 18432176 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0
Study 18432176 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 18432176 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 0
Study 16444102 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic forms of relaxation therapy (mindfulness-based stress reduction, guided imagery, hypnosis)
Number of subjects: 0
Study 14578137 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 g of fruits and vegetables
Number of subjects: 43
Study 14578137 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins and minerals supplement
Number of subjects: 43
Study 14578137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 11006063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, self-help dietary intervention (computer-generated personalized letter, motivational phone call, self-help manual, supplementary materials, behavioral feedback, newsletters)
Number of subjects: 1459
Study 11006063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, self-help dietary intervention
Number of subjects: 1459
Study 11006063 — intervention group
Group type: COMPARATOR
Intervention: No materials (control group)
Number of subjects: 1459
Study 8925327 — intervention group
Group type: EXPERIMENTAL
Intervention: Original method of determining rectal compliance using a balloon inflated to 60 ml
Number of subjects: 130
Study 8925327 — intervention group
Group type: EXPERIMENTAL
Intervention: Original method of determining anal canal compliance using a ring-shaped balloon inflated to 12 ml
Number of subjects: 130
Study 1513728 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (dicloxacillin, cephalexin, or erythromycin orally for seven days)
Number of subjects: 185
Study 1513728 — intervention group
Group type: COMPARATOR
Intervention: Control group (local wound care only)
Number of subjects: 185
Study 1513728 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (for full thickness wounds)
Number of subjects: 185
Study 1513728 — intervention group
Group type: COMPARATOR
Intervention: Control group (for full thickness wounds)
Number of subjects: 185
Study 3010383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.125 mg/70 kg)
Number of subjects: 7
Study 3010383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.25 mg/70 kg)
Number of subjects: 7
Study 3010383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.50 mg/70 kg)
Number of subjects: 7
Study 3010383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31272957 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid treatment (n=51; range 9-115 months)
Number of subjects: 82
Study 31272957 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (n=20; range 12-90 months)
Number of subjects: 82
Study 29482516 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group intervention by primary healthcare professionals
Number of subjects: 432
Study 29482516 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (Control)
Number of subjects: 432
Study 27299496 — intervention group
Group type: EXPERIMENTAL
Intervention: STA OP! protocol (stepwise multidisciplinary intervention)
Number of subjects: 288
Study 27299496 — intervention group
Group type: COMPARATOR
Intervention: Control group (general technical nursing skills, dementia management, and pain management training)
Number of subjects: 288
Study 23918617 — intervention group
Group type: EXPERIMENTAL
Intervention: +360 kcal/d supplement for 6 months
Number of subjects: 8
Study 23918617 — intervention group
Group type: EXPERIMENTAL
Intervention: Active women with ExMD
Number of subjects: 8
Study 23918617 — intervention group
Group type: COMPARATOR
Intervention: Eumenorrheic active controls (n = 9)
Number of subjects: 8
Study 22570062 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial task (Tetris)
Number of subjects: 69
Study 22570062 — intervention group
Group type: COMPARATOR
Intervention: No-task control condition
Number of subjects: 69
Study 25928019 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured team briefing
Number of subjects: 46
Study 25928019 — intervention group
Group type: EXPERIMENTAL
Intervention: Review of resuscitation guidelines
Number of subjects: 46
Study 25928019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 18191355 — intervention group
Group type: EXPERIMENTAL
Intervention: Centella asiatica (250, 500, and 750 mg once daily for 2 months)
Number of subjects: 28
Study 16874170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent DTPw-HBV/Hib vaccines with 10, 5, or 2.5 microg of PRP conjugated to tetanus toxoid
Number of subjects: 680
Study 16874170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent DTPw-HBV/Hib vaccines
Number of subjects: 680
Study 14513421 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily)
Number of subjects: 293
Study 14513421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 14513421 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily) and Placebo
Number of subjects: 293
Study 10710842 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward (R)
Number of subjects: 44
Study 10710842 — intervention group
Group type: EXPERIMENTAL
Intervention: Response Cost (RC)
Number of subjects: 44
Study 10710842 — intervention group
Group type: COMPARATOR
Intervention: No Contingency (NR)
Number of subjects: 44
Study 10710842 — intervention group
Group type: EXPERIMENTAL
Intervention: High-interest task
Number of subjects: 44
Study 10710842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-interest task
Number of subjects: 44
Study 8938652 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg)
Number of subjects: 8
Study 8938652 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg)
Number of subjects: 8
Study 8938652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1527255 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR Hygroster (DHS)
Number of subjects: 80
Study 1527255 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR Hygobac (DHC)
Number of subjects: 80
Study 1527255 — intervention group
Group type: COMPARATOR
Intervention: Pall Ultipor BB50 (PUBC)
Number of subjects: 80
Study 1527255 — intervention group
Group type: COMPARATOR
Intervention: Intersurgical filtatherm (IFT)
Number of subjects: 80
Study 3835164 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Gentamycin and 600 mg Lincomycin intramuscularly, two hours preoperatively, and every eight hours postoperatively for three days
Number of subjects: 90
Study 3835164 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Gentamycin and 600 mg Clindamycin intramuscularly, two hours preoperatively, and every eight hours postoperatively for three days
Number of subjects: 90
Study 3835164 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Gentamycin and 500 mg Metronidazole given over 20 minutes, two hours preoperatively, and every eight hours postoperatively for three days
Number of subjects: 90
Study 29577734 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious history taking by clinicians
Number of subjects: 66
Study 29577734 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of religious histories using the FICA assessment tool
Number of subjects: 66
Study 27450277 — intervention group
Group type: EXPERIMENTAL
Intervention: DCV 60 mg once daily for 5 days
Number of subjects: 0
Study 27450277 — intervention group
Group type: COMPARATOR
Intervention: DTG 50 mg once daily for 5 days
Number of subjects: 0
Study 24827024 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-focused intervention
Number of subjects: 155
Study 24827024 — intervention group
Group type: COMPARATOR
Intervention: Common factors intervention
Number of subjects: 155
Study 24827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based group interventions
Number of subjects: 155
Study 24827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Children without symptoms of disinhibited social engagement disorder
Number of subjects: 155
Study 24827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of parents with high levels of psychopathology
Number of subjects: 155
Study 24827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of parents with high levels of parenting stress
Number of subjects: 155
Study 22734377 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread embedding at Changqiang (GV 1)
Number of subjects: 80
Study 22734377 — intervention group
Group type: COMPARATOR
Intervention: Indometacin suppository
Number of subjects: 80
Study 20562752 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sertraline per day
Number of subjects: 60
Study 20562752 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study 18984888 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of a combination of 2.5 mg of folic acid, 50 mg of vitamin B(6), and 1 mg of vitamin B(12) (n = 2721)
Number of subjects: 5442
Study 18984888 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 2721)
Number of subjects: 5442
Study 15894946 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg per day
Number of subjects: 33
Study 15894946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 15894946 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan and Placebo
Number of subjects: 33
Study 12126865 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 52
Study 12126865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 52
Study 10424277 — intervention group
Group type: COMPARATOR
Intervention: alpha2b-interferon alone (6 months at 6 MU followed by 6 months at 3 MU three times weekly)
Number of subjects: 64
Study 10424277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ribavirin and alpha2b-interferon (2 months ribavirin followed by 2 months of ribavirin with alpha2b-interferon at 1.0 or 1.2 g daily)
Number of subjects: 64
Study 10424277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 64
Study 10424277 — intervention group
Group type: COMPARATOR
Intervention: alpha2b-interferon alone
Number of subjects: 64
Study 7574741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy (group A) with high-dose intermittent 5-FU infusion at 1,000 mg/m2 for 5 hours a week.
Number of subjects: 27
Study 7574741 — intervention group
Group type: COMPARATOR
Intervention: Usual hepatectomy (group B) without intra-arterial chemotherapy.
Number of subjects: 27
Study 2153478 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intravenous enalaprilat
Number of subjects: 43
Study 7308007 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 120
Study 7308007 — intervention group
Group type: COMPARATOR
Intervention: EPL
Number of subjects: 120
Study 7308007 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 30817329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Number of subjects: 0
Study 30817329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28112528 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (720 mg eicosapentaenoic acid plus 480 mg docosahexaenoic acid)
Number of subjects: 45
Study 28112528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (edible paraffin)
Number of subjects: 45
Study 26340282 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace initiative to reduce work-family conflict; costs of the intervention were $690 per participant.
Number of subjects: 0
Study 22904118 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐15 Intermittent Ice Test (30‐15(IIT))
Number of subjects: 10
Study 21272188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin infusion (0.5 mU/kg/min)
Number of subjects: 8
Study 21272188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin infusion (1.5 mU/kg/min)
Number of subjects: 8
Study 21272188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion (3.0 mU/kg/min)
Number of subjects: 8
Study 21272188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion (5.0 mU/kg/min)
Number of subjects: 8
Study 21272188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion (3.0 and 5.0 mU/kg/min)
Number of subjects: 8
Study 19659602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt GVL Stat
Number of subjects: 32
Study 19659602 — intervention group
Group type: COMPARATOR
Intervention: Miller laryngoscope
Number of subjects: 32
Study 17157101 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 983
Study 17157101 — intervention group
Group type: COMPARATOR
Intervention: COC
Number of subjects: 983
Study 12752054 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost 0.005%
Number of subjects: 41
Study 12752054 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brimonidine 0.2%
Number of subjects: 41
Study 10943958 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based hypo-osmolar ORS
Number of subjects: 58
Study 10943958 — intervention group
Group type: COMPARATOR
Intervention: WHO-ORS
Number of subjects: 58
Study 10943958 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based hypo-osmolar ORS
Number of subjects: 58
Study 9307711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl acetate 300,000 IU/week x 12 months)
Number of subjects: 160
Study 9307711 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (360 mg/week x 12 months)
Number of subjects: 160
Study 9307711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 3547572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins
Number of subjects: 0
Study 3547572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular immunoglobulins against Pseudomonas aeruginosa
Number of subjects: 0
Study 3547572 — intervention group
Group type: EXPERIMENTAL
Intervention: J5 antiserum to the core glycolipid of lipopolysaccharide
Number of subjects: 0
Study 3547572 — intervention group
Group type: EXPERIMENTAL
Intervention: J5 antiserum administered prophylactically to high-risk surgical patients
Number of subjects: 0
Study 29239677 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect Adventures Training Group (KATG)
Number of subjects: 46
Study 29239677 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physical Therapy Group (CPTG)
Number of subjects: 46
Study 27028133 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 94
Study 27028133 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 94
Study 25074851 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-to-patient model
Number of subjects: 89
Study 25074851 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipant group (control)
Number of subjects: 89
Study 23483627 — intervention group
Group type: EXPERIMENTAL
Intervention: istradefylline 20 mg/day
Number of subjects: 373
Study 23483627 — intervention group
Group type: EXPERIMENTAL
Intervention: istradefylline 40 mg/day
Number of subjects: 373
Study 23483627 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 373
Study 20452283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight-fasted (FAST)
Number of subjects: 14
Study 20452283 — intervention group
Group type: COMPARATOR
Intervention: Acutely fed (FED)
Number of subjects: 14
Study 18775668 — intervention group
Group type: EXPERIMENTAL
Intervention: LTA-T (750-1500 microg)
Number of subjects: 14
Study 18775668 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 14
Study 15505268 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 issues of an evidence‐based series called Therapeutics Letter (intervention group, n = 258)
Number of subjects: 499
Study 15505268 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 241)
Number of subjects: 499
Study 11462946 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of leucovorin (200 mg/m2/day), 5-fluorouracil (375 mg/m2/day), and cisplatin (15 mg/m2/day) repeated every 21 days
Number of subjects: 45
Study 11462946 — intervention group
Group type: COMPARATOR
Intervention: Supported care alone (control group)
Number of subjects: 45
Study 9781723 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (0.25 mg/hr)
Number of subjects: 40
Study 9781723 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 40
Study 9781723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8143426 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of glucose in 300 ml of water (n = 8)
Number of subjects: 39
Study 8143426 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of fat in 250 ml of water (n = 8)
Number of subjects: 39
Study 8143426 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of lean meat corresponding to 40 g of protein with 250 ml of water (n = 8)
Number of subjects: 39
Study 8143426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal (1750 kJ) (n = 8)
Number of subjects: 39
Study 8143426 — intervention group
Group type: COMPARATOR
Intervention: 300 ml of water only (n = 7)
Number of subjects: 39
Study 3262175 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative infusion of a 3% amino acid solution
Number of subjects: 18
Study 3262175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amino acid infusion)
Number of subjects: 18
Study 31871950 — intervention group
Group type: EXPERIMENTAL
Intervention: Theracurmin® (180 mg daily for 6 months)
Number of subjects: 33
Study 31871950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31871950 — intervention group
Group type: EXPERIMENTAL
Intervention: Theracurmin®
Number of subjects: 33
Study 28483174 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention (MI) including care from psychiatry, general medicine, neuropsychology, family therapy, and occupational therapy
Number of subjects: 302
Study 28483174 — intervention group
Group type: COMPARATOR
Intervention: Traditional Intervention (TI) including care from psychiatry and general medicine
Number of subjects: 302
Study 23656980 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin glargine
Number of subjects: 12537
Study 23656980 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic care
Number of subjects: 12537
Study 20456557 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound scalp formulation (calcipotriol 50 μg/g and betamethasone 0.5 mg/g)
Number of subjects: 2920
Study 20456557 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate
Number of subjects: 2920
Study 20456557 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 2920
Study 20456557 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2920
Study 18617654 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 4729
Study 17091007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral anger management program (120 minutes per session, three consecutive sessions, once a week)
Number of subjects: 26
Study 17091007 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26